Enteric fever, encompassing both typhoid and paratyphoid fever, remains a significant global health issue, particularly in low-resource settings. Despite advancements in diagnostic techniques and treatment strategies, challenges persist in managing this condition. This article aims to provide an updated approach to the diagnosis and management of enteric fever in clinical practice.
Early diagnosis of enteric fever is crucial to prevent complications and reduce morbidity. While blood culture remains the gold standard, it has limitations, such as low sensitivity and slow turnaround time. Recent advances include molecular techniques like PCR and serological tests like Typhidot and Tubex TF, which offer more rapid results. However, their utility is limited by variable sensitivity and specificity. Therefore, a high index of clinical suspicion and comprehensive patient history remain vital in guiding the diagnostic process.
The mainstay of enteric fever management is antibiotic therapy. The choice of antibiotics depends on local antimicrobial resistance patterns. Fluoroquinolones, cephalosporins, and azithromycin are commonly used. However, the emergence of extensively drug-resistant (XDR) strains poses a significant challenge, necessitating the use of newer agents like carbapenems and tigecycline.
Vaccination plays a crucial role in the prevention of enteric fever. Two vaccines, Vi polysaccharide vaccine and Ty21a, are currently available and recommended for high-risk individuals and travelers to endemic areas. Additionally, improving sanitation, safe food and water practices, and public health surveillance are essential in controlling the disease.
Enteric fever continues to pose a significant global health challenge. While advances have been made in diagnostic techniques and treatment strategies, vigilance in clinical suspicion, awareness of local antimicrobial resistance patterns, and preventive measures remain key to managing this disease effectively. Further research is needed to develop more sensitive and specific diagnostic tests and to address the growing concern of antibiotic resistance.
1.
Cancer tumor anatomy influences the benefits of chemotherapy for patients with early-stage breast cancer.
2.
FDA Investigating Blood Cancer Risk With Gene Therapy Skysona
3.
Adding Lenvatinib to Pembro Ups PFS in Head and Neck Cancer
4.
In early dementia, SSRIs enhance cognition and major depression.
5.
TCL1A Protein Identified as Predictor of Blinatumomab Response in Relapsed B-ALL
1.
Oncologic Emergencies: Diagnosis and Treatment
2.
Strategic Standards in Hematology for Specialists
3.
Emerging Chemo-Immunotherapy: New Agents and Mechanisms in Modern Oncology
4.
Advanced Breakthroughs in Hematology and Patient Outcomes
5.
Multidisciplinary Insights into Diagnosis, Management, and Outcomes in Oncology
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Navigating the Complexities of Ph Negative ALL - Part IX
2.
A Continuation to The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma
3.
Current Scenario of Cancer- An Overview of The Incidence of Cancer in Men
4.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part II
5.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part III
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation